The distribution of oral coagulant Eliquis (apixaban) tablets in Japan will no longer be handled by BMS and will be taken over by Pfizer Dec. 1, the two companies announced Oct. 18. BMS will continue to be in charge of manufacturing and both companies will continue with education, but Pfizer will take over all distribution to medical institutions. After a six-month postmarketing surveillance period that ended in August, both companies decided to expand their information provision activities. Taking advantage of Pfizer’s distribution networks in the primary care area and entrusting them with Eliquis sales will allow BMS to focus on information provision and improve efficacy. (Click Here For More – Japanese Language
)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?